BR112023023965A2 - Método terapêutico para um gato com doença renal crônica, e, agente terapêutico - Google Patents

Método terapêutico para um gato com doença renal crônica, e, agente terapêutico

Info

Publication number
BR112023023965A2
BR112023023965A2 BR112023023965A BR112023023965A BR112023023965A2 BR 112023023965 A2 BR112023023965 A2 BR 112023023965A2 BR 112023023965 A BR112023023965 A BR 112023023965A BR 112023023965 A BR112023023965 A BR 112023023965A BR 112023023965 A2 BR112023023965 A2 BR 112023023965A2
Authority
BR
Brazil
Prior art keywords
kidney disease
chronic kidney
feline
therapeutic
cat
Prior art date
Application number
BR112023023965A
Other languages
English (en)
Portuguese (pt)
Inventor
Hajimu Kurumatani
Takumi Matsuura
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112023023965A2 publication Critical patent/BR112023023965A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023023965A 2021-06-16 2022-06-15 Método terapêutico para um gato com doença renal crônica, e, agente terapêutico BR112023023965A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021100475 2021-06-16
PCT/JP2022/023876 WO2022265031A1 (ja) 2021-06-16 2022-06-15 慢性腎臓病のネコの治療方法

Publications (1)

Publication Number Publication Date
BR112023023965A2 true BR112023023965A2 (pt) 2024-01-30

Family

ID=84527566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023965A BR112023023965A2 (pt) 2021-06-16 2022-06-15 Método terapêutico para um gato com doença renal crônica, e, agente terapêutico

Country Status (11)

Country Link
US (1) US12097177B2 (https=)
EP (1) EP4356908B1 (https=)
JP (1) JP7318818B2 (https=)
KR (1) KR20240021749A (https=)
CN (1) CN117396197A (https=)
AU (1) AU2022294552A1 (https=)
BR (1) BR112023023965A2 (https=)
CA (1) CA3217697A1 (https=)
ES (1) ES3054744T3 (https=)
MX (1) MX2023013545A (https=)
WO (1) WO2022265031A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501556A (ja) * 2021-12-27 2025-01-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 慢性腎臓病を診断及び治療するための組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
JPH075582B2 (ja) 1986-01-24 1995-01-25 東レ株式会社 2,5,6,7−テトラノル−4,8−インタ−m−フエニレンPGI▲下2▼誘導体
JPH0662599B2 (ja) 1987-10-16 1994-08-17 東レ株式会社 2,5,6,7―テトラノル―4,8―インタ―m―フェニレンPGI2誘導体ならびにその製造法および用途
CA2012081C (en) 1989-03-14 2000-08-29 Shigeki Itou 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives
WO1998041210A1 (en) 1997-03-14 1998-09-24 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
ES2272914T3 (es) 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
CN101217960B (zh) 2005-07-08 2010-12-15 东丽株式会社 用于改善尿毒症的治疗药和处置方法
JPWO2016031949A1 (ja) 2014-08-28 2017-06-22 東レ株式会社 慢性腎不全の治療薬
CA3164676A1 (en) 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death

Also Published As

Publication number Publication date
MX2023013545A (es) 2023-11-29
EP4356908A4 (en) 2024-10-23
US12097177B2 (en) 2024-09-24
WO2022265031A1 (ja) 2022-12-22
EP4356908A1 (en) 2024-04-24
CA3217697A1 (en) 2022-12-22
JP7318818B2 (ja) 2023-08-01
AU2022294552A1 (en) 2023-11-02
CN117396197A (zh) 2024-01-12
JPWO2022265031A1 (https=) 2022-12-22
US20240207218A1 (en) 2024-06-27
EP4356908C0 (en) 2025-10-22
ES3054744T3 (en) 2026-02-05
KR20240021749A (ko) 2024-02-19
EP4356908B1 (en) 2025-10-22
TW202317089A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
NZ777871A (en) Small molecule modulators of il-17
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
BRPI0408784A (pt) método para usar um composto
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
JOP20190008A1 (ar) علاج ومنع اضطرابات النوم
BR112015020823A2 (pt) 1-hidróxi-benzooxaboróis como agentes antiparasíticos
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BRPI0713743C1 (pt) composto, e, composição farmacêutica
BRPI0607536A2 (pt) tratamento de dor
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer
BR112023023965A2 (pt) Método terapêutico para um gato com doença renal crônica, e, agente terapêutico
BR112021022966A2 (pt) Método para reduzir o tamanho do tumor
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
BR112015027569A2 (pt) compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
CO2024002712A2 (es) Azálidos inmunomoduladores

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]